Bio-Rad Laboratories, Inc.
BIO · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $7,549 | $6,570 | $6,805 | $9,197 |
| - Cash | $398 | $369 | $521 | $488 |
| + Debt | $1,395 | $1,407 | $1,370 | $1,375 |
| Enterprise Value | $8,546 | $7,607 | $7,653 | $10,084 |
| Revenue | $653 | $652 | $585 | $667 |
| % Growth | 0.2% | 11.3% | -12.3% | – |
| Gross Profit | $343 | $345 | $306 | $342 |
| % Margin | 52.6% | 53% | 52.3% | 51.2% |
| EBITDA | -$385 | $477 | $134 | -$847 |
| % Margin | -58.9% | 73.2% | 22.8% | -127% |
| Net Income | -$342 | $318 | $64 | -$716 |
| % Margin | -52.4% | 48.8% | 10.9% | -107.2% |
| EPS Diluted | -12.7 | 11.67 | 2.29 | -25.57 |
| % Growth | -208.8% | 409.6% | 109% | – |
| Operating Cash Flow | $121 | $117 | $130 | $124 |
| Capital Expenditures | -$32 | -$46 | -$34 | -$43 |
| Free Cash Flow | $89 | $71 | $96 | $81 |